Breaking News Instant updates and real-time market news.

EIGR

Eiger BioPharmaceuticals

08:04
04/21/17
04/21
08:04
04/21/17
08:04

Eiger BioPharmaceuticals reports Phase 2 results for lonafarnib at ILC

Eiger BioPharmaceuticals announced additional lonafarnib data from the LOWR HDV Program presented at The International Liver Congress in Amsterdam. After 24 weeks of treatment, all-oral lonafarnib-based regimens suppressed Hepatitis Delta Virus-RNA below the limit of quantitation in 36% of patients, and 60% achieved ALT normalization. The addition of PEG IFN to LNF 25 mg BID + RTV suppressed HDV-RNA below the limit of quantitation in 80% of patients, and 78% achieved ALT normalization. In patients treated for 48 weeks with triple therapy of PEG IFN + LNF 25 mg BID + RTV, PCR-negativity was achieved in 67% of patients at the end of treatment. Additional dosing regimens were also explored in the LOWR program. Anti-HDV activity was observed in all regimens through Week 24 on treatment. HDV viral load returned to baseline in a majority of these patients by Week 24 of post-treatment, suggesting longer-term treatment of all-oral LNF + RTV or triple combination of LNF + RTV + PEG IFN may be necessary to achieve sustained antiviral suppression. Hepatitis Delta is the most aggressive form of viral hepatitis.

  • 06

    Jun

EIGR Eiger BioPharmaceuticals

07/05/16
OPCO
07/05/16
INITIATION
Target $34
OPCO
Outperform
Eiger BioPharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer analyst Carlos Solorzano started Eiger BioPharmaceuticals with an Outperform rating and $34 price target.
08/18/16
PIPR
08/18/16
NO CHANGE
Target $35
PIPR
Overweight
Eiger BioPharma raises $20M ahead of Sarasar Data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says that Eiger BioPharmaceuticals ended Q2 with $45.4M and just issued 1.25 million shares at $16.00, raising gross proceeds of $20M, which will fund development of multiple Phase 2 orphan disease candidates into 2018. Tenthoff notes that he is looking for important Phase 2 updates on Sarasar, or lonafarnib, in Hepatitis Delta Virus at AASLD, or American Association for the study of liver diseases, meeting in November. The analyst reiterates an Overweight rating on the stock but lowered his price target on the shares to $35 from $37.50 to account for dilution from the deal.
09/13/16
PIPR
09/13/16
NO CHANGE
Target $35
PIPR
Overweight
Piper sees a trading opportunity in Eiger BioPharmaceuticals
Piper Jaffray analyst Edward Tenthoff believes the recent weakness in shares of Eiger BioPharmaceuticals has created a "compelling trading opportunity" into November's American Association for the Study of Liver Diseases meeting. Eiger will report 24-week Phase II data on Sarasar to treat Hepatitis Delta Virus at the conference, Tenthoff tells investors in a research note. The analyst expects the data to be "highly informative about future development of Sarasar." He reiterates an Overweight rating on Eiger shares with a $35 price target.
04/07/17
PIPR
04/07/17
NO CHANGE
Target $36
PIPR
Overweight
Eiger shares look attractive after selloff, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Eiger BioPharmaceuticals look attractive following yesterday's selloff. The analyst reminds investors that abstracts are often placeholders and that 48-week data on all three Phase II Sarasar studies are likely between April 19-23. The analyst reiterates an Overweight rating on the shares with a $36 price target.

TODAY'S FREE FLY STORIES

SND

Smart Sand

$6.42

0.04 (0.63%)

10:54
09/20/17
09/20
10:54
09/20/17
10:54
Conference/Events
Smart Sand participates in a conference call with Johnson Rice »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

10:53
09/20/17
09/20
10:53
09/20/17
10:53
Recommendations
Bed Bath & Beyond analyst commentary  »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOV

National Oilwell

$35.37

0.19 (0.54%)

10:52
09/20/17
09/20
10:52
09/20/17
10:52
Options
National Oilwell calls outpace puts 18:1 as shares jump »

National Oilwell calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

ZLAB

Zai Lab

10:51
09/20/17
09/20
10:51
09/20/17
10:51
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

STX

Seagate

$32.18

-1.34 (-4.00%)

10:50
09/20/17
09/20
10:50
09/20/17
10:50
Options
Short-term calls on Seagate see interest for a second time this week »

Short-term calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$237.42

-2.3252 (-0.97%)

10:47
09/20/17
09/20
10:47
09/20/17
10:47
Conference/Events
Teleflex management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 01

    Dec

OFIX

Orthofix

$48.51

-0.49 (-1.00%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Conference/Events
Orthofix management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

PFE

Pfizer

$35.93

0.475 (1.34%)

10:45
09/20/17
09/20
10:45
09/20/17
10:45
Options
Pfizer call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 18

    Oct

  • 31

    Oct

10:45
09/20/17
09/20
10:45
09/20/17
10:45
General news
Euro$ interest rate futures are relatively buoyant »

Euro$ interest rate…

ZLAB

Zai Lab

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Syndicate
Breaking Syndicate news story on Zai Lab »

Zai Lab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

NKTR

Nektar

$21.75

-0.85 (-3.76%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Conference/Events
Nektar management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 25

    Sep

MAT

Mattel

$15.05

0.18 (1.21%)

, HAS

Hasbro

$94.99

1.75 (1.88%)

10:44
09/20/17
09/20
10:44
09/20/17
10:44
Hot Stocks
Toymakers in focus after Toys"R"Us files for bankruptcy, Amazon could benefit »

Shares of toymakers,…

MAT

Mattel

$15.05

0.18 (1.21%)

HAS

Hasbro

$94.99

1.75 (1.88%)

JAKK

JAKKS Pacific

$2.83

-0.025 (-0.88%)

KKR

KKR

$19.24

0.15 (0.79%)

VNO

Vornado

$73.34

-0.03 (-0.04%)

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

WMT

Wal-Mart

$80.29

0.24 (0.30%)

JPM

JPMorgan

$94.12

0.18 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

  • 10

    Oct

  • 12

    Oct

  • 22

    Oct

  • 23

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

MODN

Model N

$13.35

-0.15 (-1.11%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Conference/Events
Model N management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 16

    Nov

MMM

3M

$210.50

-3.06 (-1.43%)

10:43
09/20/17
09/20
10:43
09/20/17
10:43
Hot Stocks
Analyst says sell 3M amid slowdown in autos, electronics »

JPMorgan downgraded 3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

ODP

Office Depot

$4.35

-0.07 (-1.58%)

, ADP

ADP

$107.48

0.93 (0.87%)

10:42
09/20/17
09/20
10:42
09/20/17
10:42
Hot Stocks
Office Depot says David Bleisch joins as Chief Legal Officer »

Office Depot (ODP)…

ODP

Office Depot

$4.35

-0.07 (-1.58%)

ADP

ADP

$107.48

0.93 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZLAB

Zai Lab

10:40
09/20/17
09/20
10:40
09/20/17
10:40
Syndicate
Zai Lab indicated to open at $23, IPO priced at $18 »

Zai Lab (ZLAB) priced 8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

10:40
09/20/17
09/20
10:40
09/20/17
10:40
General news
Energy Action: NYMEX crude »

Energy Action: NYMEX…

APC

Anadarko

$44.64

0.88 (2.01%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JCOM

j2 Global

$73.37

-1.52 (-2.03%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Conference/Events
j2 Global management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

PFE

Pfizer

$35.85

0.4 (1.13%)

, JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

10:34
09/20/17
09/20
10:34
09/20/17
10:34
Hot Stocks
Pfizer takes J&J to court as analysts shake up pharma ratings »

Morgan Stanley analyst…

PFE

Pfizer

$35.85

0.4 (1.13%)

JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

LLY

Eli Lilly

$82.24

0.505 (0.62%)

NVS

Novartis

$86.11

0.26 (0.30%)

ABBV

AbbVie

$86.90

0.53 (0.61%)

BMY

Bristol-Myers

$63.08

0.1532 (0.24%)

AGN

Allergan

$211.28

-3.725 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

  • 18

    Oct

  • 26

    Oct

  • 31

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.